Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis

Więdłocha, Magdalena; Marcinowicz, Piotr; Krupa, Renata; Janoska-Jaździk, Marlena; Janus, Marta; Dębowska, Weronika; Mosiołek, Anna; Waszkiewicz, Napoleon; Szulc, Agata

doi:10.1016/j.pnpbp.2017.04.026

Cited by 166 publications

(102 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma CRP and cytokine levels in our sample were consistent with those of other studies exploring inflammation depressed patients but there was a high variability between Ala‐carriers and Val/Val‐carriers for these parameters.…”

Section: Discussionsupporting

confidence: 90%

“…Several clinical investigations and preclinical studies suggest that inflammatory processes are correlated and could be involved in the onset and/or the progression of MDD, and thus, inflammatory proteins could be used as MDD biomarkers . Indeed, in a large meta‐analysis, interleukin‐6 (IL‐6) and tumour necrosis factor‐alpha (TNF‐alpha), two major pro‐inflammatory cytokines, exhibit higher plasma levels in depressed patients compared to controls . Similarly, C‐reactive protein (CRP) plasma levels are higher in depressed patients than in healthy volunteers .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SOD2 genetic polymorphism (rs4880) has no impact on 6‐month response to antidepressant treatment and inflammatory biomarkers in depressed patients

Tayeb

Becquemont

El‐Asmar

et al. 2020

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Two thirds of patients suffering from a major depressive episode (MDE) do not reach a complete response with antidepressant drugs. This lack of response is due to several factors, including genetic determinants. Since major depressive disorder is associated with inflammatory and oxidative stress abnormalities, the metabolism of superoxide anions might be involved in non‐response to antidepressant drugs. Superoxide anions are metabolized by manganese‐dependent superoxide dismutase (SOD2) in the mitochondria. A functional genetic polymorphism (SOD2, rs4880), responsible of a 40% reduction in enzyme activity, is associated with anti‐inflammatory response of rosuvastatin. We investigated the association of ala‐allele of SOD2 rs4880 and both antidepressant efficacy and inflammatory parameters in patients treated for a MDE with antidepressant drugs. The Hamilton Depression Rating Scale (HDRS) score and levels of plasma CRP and inflammatory cytokines were assessed at baseline, one month (M1), 3 months (M3) and 6 months (M6) after antidepressant treatment. They were compared according to SOD2 genetic polymorphism. Of the 484 patients studied, 361 (74.6%) carried the ala‐allele (Ala group), 123 (25.4%) of them had Val/Val genotype (Val/Val group). No significant difference was observed between the Ala and Val/Val groups neither for baseline clinical characteristics, nor for HDRS scores, response/remission rates, plasma CRP and cytokine levels throughout the study. The rs4880 SOD2 genetic polymorphism was not associated with the clinical response and cytokines levels after antidepressant treatment. These data suggest that SOD2 is not a major genetic determinant of antidepressant response. Other genes of the oxidative stress pathways should be explored in further studies.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

SOD2 genetic polymorphism (rs4880) has no impact on 6‐month response to antidepressant treatment and inflammatory biomarkers in depressed patients

Tayeb

Becquemont

El‐Asmar

et al. 2020

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…In another study, the administration of a saffron extract dose-dependently increased brain concentrations of dopamine, and at high doses increased glutamate levels; however, it had no effect on serotonin or norepinephrine concentrations (Ettehadi et al, 2013). The monoaminergic activity of pharmaceutical antidepressants such as serotonin reuptake inhibitors is well recognised; however, recent evidence suggests that they may also have antioxidant and anti-inflammatory effects (Jimenez-Fernandez et al, 2015;Wiedlocha et al, 2017). Saffron as an adjuvant agent may be particularly pertinent as there are adult studies suggesting that lower premorbid antioxidant levels (Baek et al, 2016), and higher inflammation are associated with increased non-response from antidepressant treatment (Eller et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study

Lopresti

Drummond

Inarejos-García³

et al. 2018

Journal of Affective Disorders

View full text Add to dashboard Cite

Esta es la versión de autor del artículo publicado en: This is an author produced version of a paper published in:Journal of Affective Disorders 232 (2018) However, this is the first study examining its mood-related effects in teenagers. MethodsIn this 8-week, randomised, double-blind, placebo-controlled study, youth aged 12 to 16 years, with mild-to-moderate anxiety or depressive symptoms were given tablets containing placebo or a saffron extract (affron ® , 14mg b.i. d). The youth and parent versions of the Revised ChildAnxiety and Depression Scale (RCADS) were used as outcome measures.Results 80 participants were enrolled and 68 completed the study. Based on youth self-reports, affron ® was associated with greater improvements in overall internalising symptoms (p = .049), separation anxiety (p = .003), social phobia (p = .023), and depression (p = .016). Total internalising scores decreased by an average of 33% compared to 17% in the placebo group (p=.029). However, parental reports of improvements were inconsistent as mean improvements in RCADS scores were greater in the saffron group (40% vs 26%) (p=.026), although no other significant differences were identified. affron ® was well-tolerated and there was a trend of reduced headaches in participants on the active treatment.Limitations: The use of a self-report instrument, limited study duration, single treatment dose, and non-clinical sample used in this study limit the generalisability of study findings. ConclusionThe administration of a standardised saffron extract (affron ® ) for 8 weeks improved anxiety and depressive symptoms in youth with mild-to-moderate symptoms, at least from the perspective of the adolescent. However, these beneficial effects were inconsistently corroborated by parents.

show abstract

“…As mood disorders are commonly treated using psychotropic medications, it has been necessary to assess how such medications affect TNF expression and activity. Interestingly, recent meta‐analyses have reported both slightly reduced and unchanged levels of serum TNF after antidepressant treatment in individuals with major depression. These different outcomes might be due to methodological differences in completing the meta‐analyses, including the use of different statistical tests, as well as varied inclusion and exclusion criteria.…”

Section: Targeting Tnf Pathways In Mood Disorder Pharmacotherapymentioning

confidence: 99%

“…These different outcomes might be due to methodological differences in completing the meta‐analyses, including the use of different statistical tests, as well as varied inclusion and exclusion criteria. There were also significant differences in the number of studies included in the two different meta‐analyses; one meta‐analysis included data from 40 studies compared with the second meta‐analysis which included data from 16 studies. Thus, based on the study with greater statistical power, it could be concluded there is a slight reduction in TNF after antidepressant drug treatment.…”

Section: Targeting Tnf Pathways In Mood Disorder Pharmacotherapymentioning

confidence: 99%

Tumor necrosis factor receptor 2: A potential target for antidepressant drug development

Seymour

Gibbons

Dean

2019

Clinical & Exp Neuroim

View full text Add to dashboard Cite

A large body of work implicates cytokines and their related pathways in the pathophysiologies of mood disorders. Much of the data on the role of cytokines in major depression and bipolar disorder suggest that pathways regulated by tumor necrosis factor (TNF)‐α make a significant contribution to their pathophysiologies. In the present review, we contrast the well‐established role of TNF‐related pathways acting to mediate classic pro‐inflammatory cytokine activity with growing evidence that such pathways have more diverse functions in the human central nervous system. Here, it will be argued that changes in levels of the TNF receptor type 2 in mood disorders would be consistent with a neuroprotective role for the receptor against the pathophysiologies of mood disorders. This hypothesis is of significance when considering how interventions that act to modulate TNF‐regulated pathways can be used to treat the symptoms of mood disorders.

show abstract

Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis

Cited by 166 publications

References 58 publications

SOD2 genetic polymorphism (rs4880) has no impact on 6‐month response to antidepressant treatment and inflammatory biomarkers in depressed patients

SOD2 genetic polymorphism (rs4880) has no impact on 6‐month response to antidepressant treatment and inflammatory biomarkers in depressed patients

affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study

Tumor necrosis factor receptor 2: A potential target for antidepressant drug development

Contact Info

Product

Resources

About